← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Radikal Therapeutics, Inc.
West Tisbury, MA
$25,188,355
Total funding
35
Grants
Funding over time
peak $4.6M · FY2011–19$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$25,188,355 · 35
By mechanism
R44$12,102,035 · 7
R43$7,208,363 · 26
U01$5,877,957 · 2
Investigators at Radikal Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Bifunctional Redox Catalyst & Organic Nitrate for Limb Reperfusion$2,163,046
R44 · FY2013 · HL
A potassium-ATP channel opener for prevention of contrast-induced nephropathy$1,527,261
R44 · FY2014 · DK
Treatment of congenital heart disease associated pulmonary hypertension$1,500,000
R44 · FY2015 · HD
Restoration of free radical homeostasis: novel therapy of septic shock$1,248,631
R44 · FY2016 · GM
Restoration of free radical homeostasis: novel therapy of septic shock$1,194,948
R44 · FY2017 · GM
A novel immunotolerizing therapy for autoimmune vitiligo$1,039,086
R44 · FY2017 · AR
Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur$821,853
U01 · FY2018 · ES
Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur$810,596
U01 · FY2015 · ES
Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur$781,772
U01 · FY2017 · ES
Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur$774,459
U01 · FY2014 · ES
A pro-resolution lipid mediator for treatment of rheumatoid arthritis$750,000
R44 · FY2017 · AR
A pro-resolution lipid mediator for treatment of rheumatoid arthritis$750,000
R44 · FY2016 · AR
Bifunctional K-ATP channel opener and redox catalyst for treatment of hemorrhagic shock$749,330
R44 · FY2017 · GM
Bifunctional K-ATP channel opener and redox catalyst for treatment of hemorrhagic shock$719,358
R44 · FY2018 · GM
Multifunctional therapeutics for treatment of acute chlorine inhalational injury$681,561
U01 · FY2012 · ES
Multifunctional therapeutics for treatment of acute chlorine inhalational injury$677,936
U01 · FY2011 · ES
Multifunctional therapeutics for treatment of acute chlorine inhalational injury$648,083
U01 · FY2013 · ES
Multifunctional therapeutics for treatment of acute chlorine inhalational injury$644,944
U01 · FY2014 · ES
A novel immunotolerizing therapy for autoimmune vitiligo$460,375
R44 · FY2019 · AR
A Redox-active PARP Inhibitor for Lung Transplantation$390,713
R43 · FY2012 · HL